# Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9

> **NCT01388075** · NA · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 150 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT01388075
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-07
- **Primary completion:** 2018-06
- **Final completion:** —
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2011-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01388075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01388075, "Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01388075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*